Quick Answer
Passage BIO, Inc. reported R&D Expense of $23.28 million for fiscal year 2025.
Passage BIO, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $23.28M | -42.1% |
| 2024 | $40.18M | -34.6% |
| 2023 | $61.42M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.31M | -50.2% | -25.9% |
| June 30, 2025 | $5.81M | -44.3% | -24.9% |
| March 31, 2025 | $7.74M | -32.9% | -10.6% |
| September 30, 2024 | $8.66M | — | -17.0% |
| June 30, 2024 | $10.43M | — | -9.6% |
| March 31, 2024 | $11.54M | — | -12.1% |
| March 31, 2020 | $13.12M | — | — |
- Passage BIO, Inc. showed a decrease of -42.1% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Passage BIO, Inc.’s r&d expense has declined by 62.1% (from $61.42 million to $23.28 million).
- The most recent figure is from Passage BIO, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: